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Abstract 
Study Objective: As variability in vancomycin dosing, susceptibility, and tolerability has driven 
the need to compare newer agents with vancomycin in real-world clinical settings, we sought to 
quantify the effectiveness of linezolid compared with vancomycin on clinical outcomes for the 
treatment of methicillin-resistant Staphylococcus aureus (MRSA) pneumonia.  
Design: Retrospective cohort study. 
Data Source: Veterans Health Administration national databases. 
Patients: Adults admitted to Veterans Affairs hospitals between January 2002 and September 
2010 with diagnosis codes for MRSA and pneumonia, and who initiated and received at least 3 
days of continuous intravenous vancomycin therapy (4943 patients) or intravenous or oral 
linezolid therapy (328 patients) while in the hospital. 
Measurements and Main Results: Propensity score–adjusted Cox proportional hazards 
regression models quantified the effect of linezolid compared with vancomycin on time to 30-day 
mortality (primary outcome), therapy change, hospital discharge, discharge from intensive care, 
intubation, 30-day readmission, and 30-day MRSA reinfection. In addition, a composite outcome 
of clinical success was defined as discharge from the hospital or intensive care unit by day 14 
after treatment initiation, in the absence of death, therapy change, or intubation by day 14. 
Subgroup analyses were performed in a validated microbiology-confirmed MRSA subgroup and 
clinical subgroup meeting clinical criteria for infection. Although a number of baseline variables 
differed significantly between the vancomycin and linezolid treatment groups, balance was 
achieved within propensity score quintiles. A significantly lower rate of therapy change was 
observed in the linezolid group (adjusted hazard ratio [HR] 0.68, 95% confidence interval [CI] 
0.48–0.96). The clinical success rate was significantly higher among patients treated with 
linezolid (adjusted HR 1.25, 95% CI 1.07–1.47). Comparable findings were observed in the 
subgroup analyses.  
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Conclusion: Individual clinical outcomes were similar among patients treated for MRSA 
pneumonia with linezolid compared with vancomycin. A significantly higher rate of the 
composite outcome of clinical success was observed, however, among patients treated with 
linezolid compared with vancomycin. 
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Methicillin-resistant Staphylococcus aureus (MRSA) is an important cause of pneumonia, which 
is concerning because hospital-acquired pneumonia and ventilator-associated pneumonia 
(VAP) caused by MRSA are associated with significant morbidity and mortality.1-3 For more than 
50 years, the glycopetide antibiotic vancomycin has been considered the standard of care for 
MRSA infections.4,5 Unfortunately, vancomycin may be a suboptimal therapeutic option because 
of increasing minimum inhibitory concentrations among MRSA strains, poor penetration into 
alveolar fluid, and high clinical failure rates.6-12 These limitations have led to the need for 
additional therapeutic options. 
Currently, vancomycin and linezolid are the only agents with activity against MRSA that 
are approved for the treatment of nosocomial pneumonia in the United States and Europe. Thus 
far, studies comparing the efficacy of these two drugs for the treatment of pneumonia have 
demonstrated conflicting results. Although some studies have shown benefits for linezolid 
treatment compared with vancomycin,13,14 many have found that the two drugs to have 
equivalent efficacy.15-19 A recent, prospective, randomized controlled trial of culture-confirmed 
MRSA nosocomial pneumonia showed benefits for linezolid over vancomycin for clinical 
success, but no significant differences in mortality.20 Limitations of these studies, specifically 
their methodological and statistical approaches, have been noted in multiple commentaries.21-28  
These randomized trials provide important comparative efficacy data; however, they may 
not reflect the effectiveness of these agents in real-world clinical practice. MRSA pneumonia is 
a complex disease with significant morbidity and mortality; therefore, evaluating real-world 
effectiveness in treating this disease is essential. Thus, we sought to quantify the effectiveness 
of linezolid compared with vancomycin on clinical outcomes for the treatment of MRSA 
pneumonia in a national Veterans Affairs (VA) cohort. 
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Methods 
The study design and methods were defined a priori in the study protocol, which was reviewed 
and approved by the Institutional Review Board and Research and Development Committee of 
the Providence Veterans Affairs Medical Center (Providence, RI).  
Data Sources  
The Veterans Health Administration has used an electronic medical record system since 1999. 
Our study included national standardized databases capturing the following data relevant to 
patient care: International Classification of Diseases, Ninth Revision (ICD-9) diagnostic and 
procedure codes, pharmacy records (for prescriptions), laboratory tests and select laboratory 
results, mortality, and patients’ vital signs.29,30 
Patient Population and Study Design 
We conducted a retrospective cohort study of adults (aged ≥ 18 years) admitted to VA hospitals 
between January 1, 2002, and September 30, 2010, with an ICD-9 code for MRSA (038.12, 
041.12, 482.42, V09.0) and pneumonia (482.40-482.42, 482.49, 482.89, 482.9, 484.8, 485-486, 
510.0, 510.9, 513.0-513.1). Those patients who initiated and received at least 3 days of 
continuous intravenous vancomycin or intravenous or oral linezolid therapy while in the hospital 
were included in the analysis. Initiation in the hospital setting was defined as the absence of 
linezolid or vancomycin therapy in the 7 days prior to starting therapy during the hospital 
admission. Patients who died or were discharged within 3 days of treatment initiation, were 
given vancomycin or linezolid in the nursing home, or were exposed to more than 2 consecutive 
days of another antibiotic therapy with anti-MRSA activity (clindamycin, daptomycin, 
doxycycline, linezolid, minocycline, tigecycline, trimethoprim-sulfamethoxazole, vancomycin) in 
the 3 days before treatment initiation or during treatment with linezolid or vancomycin were 
excluded. Only the first admission within the study period meeting all inclusion and exclusion 
criteria was included.  
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To validate our selection criteria for the study population, we conducted several 
subgroup analyses. From the overall cohort, we identified a validated microbiology-confirmed 
MRSA subgroup and clinical subgroup. To validate the MRSA and pneumonia diagnosis codes, 
a manual electronic chart review on a random sample of 10% of all patients was completed. The 
validated population included patients with an MRSA-positive culture from a suitable sputum 
culture (<10 squamous epithelial cells and ≥25 leukocytes, or taken by an invasive technique 
such as bronchoalveolar lavage) and patients from medical centers that achieved an average 
validation of 80%. The clinical subgroup included patients with one of the following clinical 
factors between admission day and treatment initiation: presence of a chest radiograph, 
elevated body temperature (≥100.4°F), or elevated white blood cell count (≥ 10 x 103/mm3).  
Definitions of Outcomes 
The primary outcome measure was time to death (all-cause mortality) occurring within 30 days 
of treatment initiation. Secondary outcomes included time to each of the following events: 
therapy change, hospital discharge, intensive care unit (ICU) discharge, intubation, 30-day 
readmission, 30-day MRSA reinfection, and clinical success as defined below. Date of therapy 
initiation was used to define the index date of treatment. Time to therapy change, hospital 
discharge, ICU discharge, and intubation were calculated from the index date to the event date 
for each outcome. Postdischarge outcomes, including 30-day readmission and 30-day MRSA 
reinfection, were calculated in the 30 days after hospital discharge. Therapy change was 
defined as the discontinuation of linezolid or vancomycin and initiation of a different agent with 
activity against MRSA. As such, therapy change could have included switching from linezolid to 
vancomycin, switching from vancomycin to linezolid, or switching from either linezolid or 
vancomycin to another anti-MRSA antibiotic (listed above). Switching an antibiotic from 
intravenous to oral route was not considered a therapy change. Clinical rationale for therapy 
change was not ascertained.  Transfer out of the ICU was assessed among patients initiating 
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linezolid or vancomycin therapy in the ICU. For all time-dependent variables, we censored 
patients on their date of death (if death occurred) or December 31, 2010, whichever occurred 
sooner. 
Clinical success was a composite outcome defined as discharge from the hospital or 
ICU by day 14 after treatment initiation in the absence of death, therapy change, or intubation 
by day 14. Nonsuccess was defined as therapy change, intubation, ICU admission, discharge 
and readmission, or death between treatment initiation and day 14. Patients not meeting either 
definition were excluded. Day 14 was chosen to replicate the average end-of-treatment time 
frame from existing linezolid and vancomycin clinical trials.15,16,20 Sensitivity analyses evaluated 
an alternate definition of clinical success excluding therapy change. 
 
Statistical Analysis 
Between-group differences were assessed using χ2 or Fisher exact tests for categorical 
variables and the t-test or Wilcoxon rank sum test for continuous variables as appropriate. 
Propensity scores were derived from unconditional logistic regression models.  Time-to-event 
analyses were conducted with Cox proportional hazards regression models. Adjustment was 
achieved by controlling for propensity score quintiles. The propensity adjusted–Cox proportional 
hazards regression models were used to quantify the effect of linezolid compared with 
vancomycin treatment for MRSA pneumonia on the primary and secondary outcomes. A hazard 
ratio (HR) greater than 1 indicates a higher probability of the event occurring in the linezolid 
group compared with the reference vancomycin group. In terms of our study outcomes, HRs 
greater than 1 would represent a higher mortality rate, decreased length of stay (LOS), or higher 
readmission rate among patients treated with linezolid. All analyses were performed by using 
SAS statistical software, version 9.1.3 (SAS Institute Inc., Cary, NC). 
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Results 
We identified 5271 patients who met our inclusion criteria, of whom 328 (6.2%) were treated 
with linezolid and 4943 (93.8%) with vancomycin. The mean patient age was 69 years in both 
treatment groups (Table 1). The majority of patients in both groups were white men. Several 
statistically significant differences in frequency of comorbidities, including renal disease, cancer, 
and dialysis, were observed between treatment groups. Geographic region of facility and  
infections in the year prior to admission were characteristics that varied significantly between 
the linezolid and vancomycin groups (Table 2). Although a number of baseline variables differed 
significantly between the treatment groups, balance was achieved within propensity score 
quintiles. The propensity score controlled for a number of patient demographics and 
comorbidities present during the MRSA pneumonia admission, as well as medical history in the 
year prior to the MRSA pneumonia admission. Several treatment-related characteristics were 
also controlled for, including time to treatment initiation, year of treatment initiation, hospital unit 
at treatment initiation, and treating specialty at initiation.  
In the overall cohort, the 30-day mortality rate was 20.8% (19.5% linezolid vs 20.9% 
vancomycin, p=0.56). Time to 30-day mortality did not vary significantly between treatment 
groups (adjusted HR 0.91, 95% CI 0.70–1.17) (Table 3). A significantly lower rate of therapy 
change, specifically discontinuation of linezolid or vancomycin and initiation of a different anti-
MRSA agent, among linezolid-treated patients was observed in the adjusted model (HR 0.68, 
95% CI 0.48–0.96). Rates of hospital discharge, ICU discharge, intubation, 30-day MRSA 
reinfection, and 30-day readmission did not differ significantly in either the unadjusted or 
adjusted analyses. The mean ± SD time to discharge was 19.7 ± 24.4 days among linezolid-
treated patients versus 20.3 ± 26.5 days among vancomycin-treated patients. Comparable 
findings were observed in the validated and clinical subgroups. The clinical success rate was 
significantly higher among patients treated with linezolid in the overall cohort, as well as in the 
validated and clinical subgroups, as shown in Table 4: overall cohort (adjusted HR 1.25, 95% CI 
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1.07–1.47), validated subgroup (adjusted HR 1.46, 95% CI 1.13–1.87), and clinical subgroup 
(adjusted HR 1.25, 95% CI 1.03–1.52). 
   
In subgroup analyses of the overall cohort, no associations between treatment group 
and any of the study outcomes were observed among patients with renal insufficiency. Among 
obese patients in the overall cohort (123 patients in the linezolid group, 2068 patients in the 
vancomycin group), the rate of clinical success was significantly higher for linezolid-treated 
patients in the unadjusted (HR 1.57, 95% CI 1.07-2.31) and adjusted (HR 1.77, 95% CI 1.18–
2.64) analyses. In sensitivity analyses of the overall cohort excluding therapy change from the 
definition of success, linezolid was still associated with a higher rate of clinical success (179 
patients in the linezolid group, 2632 patients in the vancomycin group; unadjusted HR 1.19, 
95% CI 1.02-1.38; adjusted HR 1.18, 95% CI 1.01-1.37). 
Discussion 
 We assessed the real-world effectiveness of linezolid compared with vancomycin in the 
treatment of MRSA pneumonia in a large cohort of patients admitted to VA facilities nationally. 
No significant differences were observed in the primary outcome measure, time to 30-day 
mortality. These results regarding mortality are similar to findings from a pneumonia subset 
analysis in a large national cohort study of veterans with MRSA infections.30 In addition, these 
results are congruent with a recent clinical trial comparing linezolid with vancomycin for the 
treatment of culture-confirmed MRSA pneumonia, in which no significant difference was 
observed in mortality at 60 days (linezolid 15.7% vs vancomycin 17.0%).20  
In our study, linezolid was associated with greater clinical success, a composite outcome 
measure, compared with vancomycin.  Our definition of clinical success was defined a priori 
based on recently published clinical trials.15,16,20 Several clinical trials have demonstrated greater 
clinical success with linezolid; however, the definitions of success varied among trials and 
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compared with our study.13,14,20 Further, clinical success was determined by clinical judgment in 
those trials rather than by objective criteria as in our study.   
Previous retrospective infectious disease studies have developed definitions of clinical 
success or failure based on available data, such as clinical, pharmacological, microbiological, 
and laboratory measures.31-34 However, there is no consensus in the literature regarding the 
definition of clinical success, particularly regarding the time of evaluation and specific 
parameters to include in the measure.31-34 The clinical success definition we used in our study is 
an algorithm based on objective criteria derived from the individual outcomes collected 
(mortality, discharge, intubation, therapy change, readmission). Our sensitivity analyses of an 
alternate definition of success, which removed therapy change as a parameter, revealed similar 
findings, although to a lower magnitude (overall HR 1.25; excluding therapy change, HR 1.18), 
of an association between linezolid and clinical success. In addition to traditional outcome 
measures, such as mortality, length of stay, and pharmacoeconomics, it is useful to develop 
outcome measures that are clinically or microbiologically based to assess differences between 
groups and to assist in clinical decision making. As the prevalence of retrospective clinical 
studies increase, it is likely that these measures will evolve and be validated over time.31 
We did not observe an association between linezolid treatment and a higher discharge 
rate for MRSA pneumonia, and thus mean LOS was comparable between treatment groups 
(linezolid 19.7 days, vancomycin 20.3 days). This finding differs from an earlier national MRSA 
cohort study, in which linezolid treatment was associated with a shorter LOS.30 In general, 
evidence from randomized studies demonstrates a shorter LOS with linezolid treatment.35,36 
However, these studies included patients with other types of infections, such as complicated 
skin and soft tissue infections. MRSA pneumonia is a complicated infection with lengthy 
recommended treatment durations of up to 21 days, depending on the extent of the infection,37 
so it may have been less likely that we would observe differences in LOS and discharge rates in 
our study than in studies of other infection types.  
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  In our retrospective cohort study, linezolid treatment was associated with a lower rate of 
therapy change compared with vancomycin treatment in the adjusted overall analysis. Limited 
data have been published on differences in therapy change with different agents. However, in 
randomized trials, rates of discontinuation of linezolid or vancomycin were comparable to our 
findings.15,16,19 It is possible that patients receiving intravenous vancomycin may have been 
switched to a different antibiotic with an oral option as they were being prepared for discharge. 
Comparable rates of time to ICU discharge, intubation, 30-day MRSA reinfection, and 
30-day readmission were found between treatment groups in our study. In contrast, a 
prospective, open-label trial found a nonsignificant trend favoring decreased length of ICU stay 
with linezolid treatment; however, this trial limited inclusion to patients with MRSA VAP.38 In 
retrospective studies, comparable rates of intubation and readmission rates have been found 
with linezolid compared with vancomycin treatment.30,39 Few studies report readmission and 
reinfection rates due to short follow-up periods. 
 Our study has several limitations. The retrospective design is associated with a number 
of limitations, including that ICD-9 coding practices may vary among institutions and affect the 
accuracy of our findings. In addition, there is discordance with ICD-9 coding and culture-
confirmed MRSA pneumonia infection,40 thereby leading to a potential misclassification. It is 
likely our study did not capture all MRSA pneumonia infections due to missing codes for MRSA. 
Because of the complexity of obtaining microbiologic data for this study, validation of ICD-9 
codes of MRSA pneumonia was performed in a 10% patient sample. In addition, we had no 
control over culture collection. Of the patients randomly selected for validation, 29% were 
nonevaluable because no sputum samples were taken. This indicates treatment initiation for 
suspected MRSA pneumonia, based on clinical signs and symptoms, without ever collecting a 
sputum culture, which is why we also included a clinical subgroup in our analyses.  In the 
clinical subgroup, results of the chest radiographs were not available in the databases used.  
However, patients in the clinical subgroup had to meet all inclusion criteria for the overall cohort 
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in addition to having a chest radiograph between admission and initiation of treatment or one of 
the other clinical symptoms (elevated body temperature or elevated white blood cell count). 
 Our study is further limited in that we did not evaluate success in all patients since we 
excluded those not meeting the definition of success or nonsuccess by day 14 after treatment 
initiation (linezolid 29.6%, vancomycin 29.2%). It is not known whether vancomycin dosing was 
optimized among patients included in this study because trough levels were not available for 
evaluation. Although balance was achieved within propensity score quintiles, there is the 
potential for residual confounding by unobserved covariates. Finally, the generalizability of our 
study may be limited to the VA population. 
Conclusion 
 Our retrospective national cohort study demonstrated similar survival, LOS, readmission, 
and reinfection rates for patients with MRSA pneumonia treated with linezolid or vancomycin. 
Linezolid treatment was associated with a significantly higher rate of the composite outcome of 
clinical success than vancomycin. These real-world clinical data support the results of previous 
studies and further the understanding of MRSA pneumonia treatment. 
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Table 1. Demographics and Comorbid Conditions by Treatment Group  
Covariate Linezolid Group (n = 328) Vancomycin Group (n = 4943) 
Age (years) 69.1 ± 12.5 69.1 ± 12.7 
Male sex 323 (98.5) 4844 (98.0) 
Race-    
White 266 (81.1) 3945 (79.8) 
Other or unknown 62 (18.9) 998 (20.2) 
Charlson comorbidity index 2.8 ± 2.3 2.7 ± 2.3 
Comorbid conditions   
Chronic respiratory disease 140 (42.7) 2113 (42.7) 
Renal diseasea 83 (25.3) 728 (14.7) 
Diabetes mellitus 93 (28.4) 1547 (31.3) 
Heart failure 86 (26.2) 1201 (24.3) 
Coronary heart disease 83 (25.3) 1120 (22.7) 
Cancera 45 (13.7) 945 (19.1) 
Dialysisa 36 (11.0) 183 (3.7) 
Obesity 15 (4.6) 141 (2.9) 
Amputation 4 (1.2) 90 (1.8) 
Para- or quadriplegia 21 (6.4) 291 (5.9) 
Cerebrovascular disease 32 (9.8) 485 (9.8) 
Peripheral vascular disease 20 (6.1) 336 (6.8) 
Moderate or severe liver disease 6 (1.8) 93 (1.9) 
HIV/AIDS 7 (2.1) 55 (1.1) 
Bacteremiaa 52 (15.9) 1037 (21.0) 
Skin infection 88 (26.8) 1213 (24.5) 
Surgical site infection 9 (2.7) 178 (3.6) 
Data are mean ± SD or no. (%) of patients. 
HIV = human immunodeficiency virus; AIDS = acquired immunodeficiency syndrome. 
ap<0.05 for the comparison between treatment groups. 
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Table 2. Healthcare and Antibiotic Exposures and Hospitalization-Related Characteristics 
by Treatment Group 
 
Variable Linezolid Group (n = 328) 
Vancomycin Group (n = 
4943) 
Previous hospitalization in the last 
year 227 (69.2) 3368 (68.1) 
Previous hospitalization in the last 
90 days 186 (56.7) 2530 (51.2) 
Previous surgery in the last year 78 (23.8) 993 (20.1) 
Previous anti-MRSA antibiotics in 
the last 90 days 154 (47.0) 2181 (44.1) 
Previous immunosuppressants in 
the last 90 days 8 (2.4) 131 (2.7) 
Infections during the previous year   
Pneumonia 143 (43.6) 1722 (34.8) 
Chronic skin ulcer 73 (22.3) 909 (18.4) 
Bacteremiaa 36 (11.0) 303 (6.1) 
MRSA 59 (18.0) 574 (11.6) 
Pseudomonas aeruginosa 23 (7.0) 232 (4.7) 
Admission source   
Home 121 (36.9) 1771 (35.8) 
Hospital 30 (9.1) 303 (6.1) 
Nursing home 32 (9.8) 612 (12.4) 
Hospital unit at treatment initiation   
Intensive care 137 (41.8) 1998 (40.4) 
Surgery 21 (6.4) 280 (5.7) 
General medicine 170 (51.8) 2665 (53.9) 
Treating specialty   
Intensive care 142 (43.3) 1878 (38.0) 
Surgery 14 (4.3) 183 (3.7) 
General medicine 172 (52.4) 2882 (58.3) 
Region of facility   
Northa 39 (11.9) 629 (12.7) 
South 178 (54.3) 2278 (46.1) 
Midwest 65 (19.8) 953 (19.3) 
West  46 (14.0) 1083 (21.9) 
Data are no. (%) of patients. 
MRSA = methicillin-resistant Staphylococcus aureus. 
ap<0.05 for the comparison between treatment groups. 
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Table 3. Outcomes in Overall Cohort: Linezolid Compared with Vancomycin 
 
Outcome 
Unadjusted Hazard Ratio (CI) 
(linezolid group [n=328] vs 
vancomycin group [n=4942]) 
Adjusted Hazard Ratio (CI) 
(linezolid group [n=328] vs 
vancomycin group [n=4942]) 
30-day mortality 0.93 (0.72–1.20) 0.91 (0.70–1.17) 
Discharge 1.02 (0.90–1.15) 1.04 (0.92–1.18) 
Therapy change 0.75 (0.53–1.05) 0.68 (0.48–0.96) 
ICU discharge 1.03 (0.86–1.25) 1.03 (0.85–1.24) 
ICU transfer 0.65 (0.39–1.09) 0.70 (0.42–1.18) 
Intubation 0.96 (0.68–1.37) 0.97 (0.68–1.38) 
30-day MRSA reinfection 0.89 (0.54–1.48) 0.93 (0.56–1.56) 
30-day readmission 0.88 (0.68–1.13) 0.89 (0.69–1.15) 
CI = confidence interval; ICU = intensive care unit; MRSA = methicillin-resistant Staphylococcus aureus. 
The propensity score for the overall cohort was derived from an unconditional logistic regression model controlling for 
race, admission source, region of facility, hospital unit at treatment initiation, treating specialty, chronic renal disease, 
diabetes mellitus, cancer, metastatic cancer, myocardial infarction, cardiac arrhythmia, obesity, depression, 
bacteremia, endocarditis, gram-negative infection, Escherichia coli infection, Streptococcus infection, complication of 
implant or graft, complication of surgery or medical care, amputation procedure, dialysis, intravenous line, urinary 
catheter, number of inpatient procedures, time to therapy initiation, year, MRSA pneumonia diagnosis code, inpatient 
admission in the previous 30 days, procedure in the previous 180 days, previous metastatic cancer, previous 
coronary heart disease, previous congestive heart failure, previous human immunodeficiency virus infection, previous 
peripheral vascular disease, previous plegia, previous rheumatoid arthritis or connective tissue disease, previous 
peptic ulcer, previous weight loss, previous depression, previous drug abuse, previous S. aureus infection, previous 
pneumonia, previous bacteremia, previous surgical site infection, previous skin abscess, previous chronic ulcer, 
previous infective arthritis, previous vancomycin-resistant Enterococcus infection, previous E. coli infection, and 
previous intravenous line. 
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Table 4. Clinical Success of Linezolid Compared with Vancomycin 
 
Cohort Unadjusted Hazard 
Ratio (CI) 
Adjusted Hazard Ratio 
(CI) 
Overall cohort (linezolid group [n=231] 
vs vancomycin group [n=3500]) 
1.24 (1.06–1.45) 1.25 (1.07–1.47) 
Validated subgroup (linezolid group 
[n= 97] vs vancomycin group 
[n=1411]) 
1.40 (1.10–1.78) 1.46 (1.13–1.87) 
Clinical subgroup (linezolid group 
[n=165] vs vancomycin group 
[n=2536]) 
1.19 (0.98–1.44) 1.25 (1.03–1.52) 
CI = confidence interval. 
 
 
